Patent ID: 6767897
Filing Date: 2004-07-27
Classification: A61K,A61P,C07K

Abstract:
A method for treating a physiological, psychosomatic, neurological or psychiatric disorder in a patient, comprising administering to the patient at least one pentapeptide or salt thereof having a general formula (7b):R1-AA1-R2-Pro1-AA2-Gly-Trp-NH2â€ƒâ€ƒ(7b) wherein Pro1 represents the amino acid Pro; AA1 represents the amino acid Phe: AA2 represents an amino acid selected from the group consisting of D-Leu and Arg; and R1 and R2 each independently are selected from the group consisting of a hydrogen atom, a lower alkyl group having 1 to 3 carbon atoms, at least one halogen atom, a hydroxyl group, a sulphydryl group, an alkylamino group, a diakylamino group, and a cyano group wherein said disorder is selected from the group consisting of bipolar disorder, seasonal affective disorder, bulimia, anorexia nervosa, exogenous obesity, chronic fatigue syndrome, fibromyalgia, sexual dysfunction, anxiety disorder, attention deficit disorder, Parkinson's disease, schizophrenia, jet lag syndrome and addiction disorders.